The ‘goinpharma’ website seems full of bite size stories that are easily accessed, and may contain relevant sources of info for any searches (particularly on big pharma) that you might be performing. The site is new to me, but maybe not to you.
Below are two examples:
- Awesome revenue figures for Viagra - (not available OTC woldwide), but the UK alone has recently allowed Viagra OTC.
Teva launches Viagra generic in US
17 DECEMBER 2017 - 10:20
Viagra was approved by FDA in 1998 and has fetched Pfizer billions of dollars worldwide since then. Considering the 2003-2014 period, Viagra’s total revenue is $21.975bn, that is $1.83bn per year on average. Viagra is sold at $65 in the US–the richest and leading market in the world–however a shift is approaching, as generics producers have now developed their own copies of Pfizer’s blockbuster. For instance, Teva last Monday presented its generic to Viagra two years before its patent expires, thanks to a Pfizer-Teva agreement signed in December 2013. The agreement will allow Teva to launch its generic earlier, in return for royalties on sales. Pfizer has entered into a similar agreement with another generics giant–Mylan. (Source: Deutscher Apotheker Zeitung)
- Pfizers’ response after GSK and RB. failed to purchase the Consumer Healthcare division a few months back:
Pfizer to reorganize company into 3 units - 11 JULY 2018 - 15:47
Ahead of today’s opening bell, Pfizer announced big plans to reorganize the group. Starting 2019, the company will be split into 3 units: Innovative Medicines, including biosimilar and injectable drugs, and other products aimed at preventing infections in hospitals; Established Medicines, both for branded and off-label drugs; and Consumer Health. Such a reorganization follows Ian Reed’s group’s unsuccessful attempt to sell the Consumer Health unit, which has been estimated at $15bn. Starting as soon as next year, the 2 new Consumer Health and Innovative Medicines units should generate over 75% of the whole group’s revenue. According to a spokesperson, the reorganization is due to the company’s need to refocus assets.
Not only but also:
President Trump had a meeting with Pfizers’ Ian Read recently, and it has now been decided that the 8% hike in some drug prices Pfizer announced at the beginning of July 2018 will not now take place. Any price increase decisions will be finalised at year end. Pfizers share price bombed on the news.